Company profile · Public records

Kindos

Free public records show Kindos in 1 of the markets we cover. It is not a key player in our research.

0Reports naming them
1Markets in public records
0Regions & countries
See reportsGrowth in full reports

Public data

Free public data on Kindos

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

US drug approvals

6 approvals with a product on the US market

Eribulin Mesylate ANDA218930 · approved 19 Oct 2026
Dalbavancin Hydrochloride ANDA218929 · approved 26 Nov 2025
Hydralazine Hydrochloride ANDA217501 · approved 2 Jun 2025
Fluorouracil ANDA215699 · approved 6 Feb 2025
Fluorouracil ANDA216494 · approved 24 Sep 2024

Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.

See them on openFDA

Markets where public records show them

Markets we cover where free public records show Kindos: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

Pain Management Drugs

Healthcare Topics

The topics of the markets Kindos is in.

All healthcare topics

Pain

From our blog

Stories on the topics Kindos works in.

All stories

Cannabis-Based Medicines: Science and Regulation

The FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…

Read

Search all reports for Kindos All companies